Alumis
Alumis reported revenue of $24 million in fiscal 2025. Its operating margin was −1,886.9%. Free cash flow was −$370 million. It paid out $0 million in dividends and buybacks. The diluted share count rose 200.0%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Alumis does
Alumis is a clinical-stage drug developer, meaning its medicines are still being tested in people and none is approved for sale. It focuses on immune-mediated diseases, where the immune system attacks the body. It says it wants targeted treatments in place of broad immune suppression.
Its two lead candidates both block an immune-system enzyme called TYK2. The more advanced, envudeucitinib, is in late-stage trials for plaque psoriasis, a skin disease, and in a mid-stage trial for lupus. It plans to file an application with the U.S. Food and Drug Administration for psoriasis in the second half of 2026. The second, A-005, is designed to reach the brain and is in early testing. It also has an antibody, lonigutamab, for thyroid eye disease.
In May 2025 Alumis acquired ACELYRIN, a drug developer, in an all-stock deal, and ACELYRIN is now its subsidiary. Alumis has no products approved for sale and no product revenue.
Its biggest risks, as it describes them
- It has no approved products, has lost money since it started and expects larger losses.
- It will need substantial more financing, and may have to delay or cut its programs if it cannot raise it.
- Its trials may show safety or side-effect problems that delay or block approval.
- Early or topline trial data it announces may change after further checking.
- Large drug companies with approved therapies in its target diseases compete with it.
Income statement
Alumis lost money in fiscal 2025: a net loss of $243 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY23 | FY24 | FY25 |
|---|---|---|---|
| Cash and short-term investments | 49 | 288 | 308 |
| Debt incl. finance leases | — | — | — |
| Net debt (negative means net cash) | — | — | — |
| Net debt to EBITDA | — | — | — |
| Debt to equity | — | — | — |
| Interest coverage | — | — | — |
| Current ratio | 2.6x | 6.0x | 4.3x |
| Quick ratio | 2.6x | 6.0x | 4.3x |
Cash flow
Projections
Project Alumis' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
No officer, director or 10% owner of Alumis reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY24 | FY25 |
|---|---|---|
| Piotroski F-score | — | — |
| Rule of 40 | — | — |
| Altman Z'' | −3.94 | −7.78 |
| Accruals ratio | −18.2% | 33.5% |
The nine F-score tests
| Test | FY24 | FY25 |
|---|---|---|
| Net income is positive | Fail | Fail |
| Cash from operations is positive | Fail | Fail |
| Return on assets rose | — | Pass |
| Cash from operations exceeds net income | Pass | Fail |
| Debt fell relative to assets | — | — |
| Current ratio rose | Pass | Fail |
| Share count didn't rise | Fail | Fail |
| Gross margin rose | — | — |
| Revenue rose relative to assets | — | — |
| F-score | — | — |
Compare
Put Alumis side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Alumis | FY25 | — | −1,886.9% | −1,539.2% | — | — | — | |
| Verastem | FY25 | 209.1% | −550.3% | — | — | — | — | Compare |
| Aquestive Therapeutics | FY25 | −22.6% | −159.5% | −119.0% | — | — | 2 | Compare |
| Ocular Therapeutix | FY25 | −18.5% | −519.8% | −417.5% | — | — | 4 | Compare |
| Agios Pharmaceuticals | FY25 | 48.0% | −873.9% | −698.3% | — | — | — | Compare |
3 years of figures
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Income statement | |||
| Revenue | — | — | 24 |
| Revenue growth | — | — | — |
| Gross profit | — | — | — |
| Research and development | 138 | 266 | 386 |
| Operating income | −158 | −301 | −454 |
| Net income | −155 | −294 | −243 |
| Diluted EPS (US$) | −72.08 | −10.38 | −2.86 |
| Diluted shares (millions) | 2 | 28 | 85 |
| Cash flow | |||
| Cash from operations | −130 | −255 | −370 |
| Capital expenditure | 4 | 2 | 1 |
| Free cash flow | −134 | −257 | −370 |
| Dividends paid | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 |
| Stock-based compensation | 9 | 20 | 44 |
| Balance sheet at fiscal year end | |||
| Cash and short-term investments | 49 | 288 | 308 |
| Debt incl. finance leases | — | — | — |
| Total assets | 90 | 341 | 412 |
| Total liabilities | 54 | 81 | 111 |
| Shareholders' equity | −339 | 260 | 301 |
| Margins and ratios | |||
| Gross margin | — | — | — |
| Operating margin | — | — | −1,886.9% |
| Net margin | — | — | −1,011.8% |
| Free cash flow margin | — | — | −1,539.2% |
| Rule of 40 (growth + FCF margin) | — | — | — |
| Return on capital | — | — | — |
| Return on equity | — | — | −86.7% |
| Return on assets | — | −136.7% | −64.6% |
| Net debt to EBITDA | — | — | — |